Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

XYZAL Oral solution (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Xyzal 0.5 mg/ml oral solution.

Qualitative and quantitative composition

1 ml of oral solution contains 0.5 mg levocetirizine dihydrochloride. Excipients with known effect: 0.675 mg methyl parahydroxybenzoate/ml 0.075 mg propyl parahydroxybenzoate/ml 0.4 g maltitol liquid/ml ...

Pharmaceutical form

Oral solution. Clear and colourless solution.

Therapeutic indications

Xyzal 0.5 mg/ml oral solution is indicated for symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and urticaria in adults and children aged 2 years and above.

Posology and method of administration

Posology Adults and adolescents 12 years and above: The daily recommended dose is 5 mg (10 ml of solution). Elderly Adjustment of the dose is recommended in elderly patients with moderate to severe renal ...

Contraindications

Hypersensitivity to the active substance, to cetirizine, to hydroxyzine, to any other piperazine derivatives or to any of the other excipients listed in section 6.1. Severe renal impairment at less than ...

Special warnings and precautions for use

Precaution is recommended with concurrent intake of alcohol (see section 4.5). Xyzal contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed). ...

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed with levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant ...

Pregnancy and lactation

Pregnancy There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of levocetirizine in pregnant women. However, for cetirizine, the racemate of levocetirizine, a large amount ...

Effects on ability to drive and use machines

Comparative clinical trials have revealed no evidence that levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive. Nevertheless, some patients could experience ...

Undesirable effects

Clinical studies Adults and adolescents above 12 years of age In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the levocetirizine 5 mg group had at least one adverse ...

Overdose

Symptoms Symptoms of overdose may include drowsiness in adults. In children, agitation and restlessness may initially occur, followed by drowsiness. Management of overdoses There is no known specific antidote ...

Pharmacodynamic properties

Pharmacotherapeutic group: Antihistamines for systemic use, piperazine derivatives ATC code: R06AE09 Mechanism of action Levocetirizine, the enantiomer of cetirizine, is a potent and selective antagonist ...

Pharmacokinetic properties

The pharmacokinetics of levocetirizine are linear with dose- and time-independent with low inter-subject variability. The pharmacokinetic profile is the same when given as the single enantiomer or when ...

Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

List of excipients

Sodium acetate trihydrate (for pH adjustment) Glacial acetic acid (for pH adjustment) Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Glycerol 85% Maltitol liquid (E965) Saccharin sodium ...

Incompatibilities

Not applicable.

Shelf life

Shelf life: 2 years. After first opening: 3 months.

Special precautions for storage

This medicinal product does not require any special storage conditions.

Nature and contents of container

Type III amber glass bottle closed with a white polypropylene child-resistant closure in a cardboard box also containing a 10 ml oral syringe graduated at 0.25 ml (polyethylene, polystyrene). Pack sizes: ...

Special precautions for disposal and other handling

No special requirements.

Marketing authorization holder

UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire, SL1 3WE

Marketing authorization number(s)

PL 00039/731

Date of first authorization / renewal of the authorization

Date of first authorisation: 21-Mar-2007 Date of latest renewal: 06-Oct-2014

Date of revision of the text

27/03/2019

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.